CTOs on the Move

Bora Pharmaceuticals

www.bora-corp.com

 
Bora Pharmaceuticals is a premier full-service, international CGMP CDMO specializing in complex oral solid dosage (tablet & capsules), liquids (solutions, suspensions, & nasal sprays) and semi-solids (creams & gels) pharmaceutical Rx and OTC products for late-phase Clinical through Commercial manufacturing and packaging.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.bora-corp.com
  • 1000 North West Street Suite 1200
    Wilmington, DE USA 19801
  • Phone: 925.803.1080

Executives

Name Title Contact Details

Similar Companies

TEVA Pharmaceuticals

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

RxNT

RxNT is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Services of Chemung Cty.

Family Services of Chemung County is located at 1019 East Water Street, Elmira, NY 14901. We offer professional counseling, crisis, case maangement, home care and other community based supportive services to youth and adults.

Albany Molecular Research

Albany Molecular Research is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.